Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

References

• Collaboration AT, Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. DOI:10.1136/bmj.324.7329.71.
   PubMed Web of Science ®Google Scholar
• Adamski P, Koziński M, Ostrowska M, et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost. 2014;112(08):224–242. DOI:10.1160/TH13-11-0915
   PubMedGoogle Scholar
• Park H-W, Kang M-G, Ahn J-H, et al. Effects of monotherapy with clopidogrel vs. aspirin on vascular function and hemostatic measurements in patients with coronary artery disease: the prospective, crossover I-LOVE-MONO trial. J Clin Med. 2021;10(12):2720. DOI:10.3390/jcm10122720
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339. DOI:10.1016/S0140-6736(96)09457-3.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–1251. DOI:10.1056/NEJMoa0805002
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco J-B, Bartelink ML, et al. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39:763–816. 2018.
   Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–19.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215–225.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
   PubMed Web of Science ®Google Scholar
• Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurol. 2019;76:1466–1473.
   PubMed Web of Science ®Google Scholar
• Koo B-K, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:2487–2496.
   PubMed Web of Science ®Google Scholar
• Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147:108–117.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297–1309.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207–217.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940–949.
   PubMed Web of Science ®Google Scholar
• Ono M, Hara H, Kawashima H, et al. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention. 2022;18:e377–388.
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35–43.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40.
   PubMed Web of Science ®Google Scholar
• Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395:1487–1495.
   PubMed Web of Science ®Google Scholar
• Aggarwal D, Bhatia K, Chunawala ZS, et al. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. Eur Heart J Open. 2022;2:oeac019.
   PubMedGoogle Scholar
• Al-Abdouh A, Abusnina W, Mhanna M, et al. P2Y12 inhibitors versus aspirin monotherapy for long-term secondary prevention of atherosclerotic cardiovascular disease events: a systematic review and meta-analysis. Curr Probl Cardiol. 2022;47:101292.
   PubMed Web of Science ®Google Scholar
• Andò G, De Santis GA, Greco A, et al. P2Y12 Inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis. JACC: Cardiovasc Interv. 2022;15:2239–2249.
   PubMed Web of Science ®Google Scholar
• Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. JACC. 2019;74:2223–2234.
   Google Scholar
• Valgimigli M. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary artery disease (PANTHER) analysis. Presented at: 43th Congress of the European Society of Cardiology; 2022 Aug 29; Barcelona, Spain.
   Google Scholar